<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526070</url>
  </required_header>
  <id_info>
    <org_study_id>SU-02012012-9068</org_study_id>
    <nct_id>NCT01526070</nct_id>
  </id_info>
  <brief_title>Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration</brief_title>
  <official_title>Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last several years, the standard of care for wet macular degeneration has become&#xD;
      treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as&#xD;
      frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor,&#xD;
      Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained&#xD;
      anatomic and visual improvement with many fewer injections (typically monthly injections for&#xD;
      3 months, followed by every-other-month injections, and as few as 5 injections a year). The&#xD;
      purpose of this study is to determine whether patients who have switched from ranibizumab to&#xD;
      VEGF Trap-Eye have comparable results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">142</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Patients with Exudative Age-Related Macular Degeneration</arm_group_label>
    <description>Patients with eAMD who received intravitreal thearpy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of Aflibercept</intervention_name>
    <arm_group_label>Patients with Exudative Age-Related Macular Degeneration</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with exudative age-related macular degeneration&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients older than the age of 50 determined by a retinal physician at the Byers Eye&#xD;
             Institute at Stanford to have exudative AMD requiring treatment.&#xD;
&#xD;
          2. Patients with an established diagnosis of exudative AMD who have been maintained on a&#xD;
             regimen of intravitreal ranibizumab injections.&#xD;
&#xD;
          3. Postmenopausal or negative pregnancy test&#xD;
&#xD;
          4. Patients with an established diagnois of exidative AMD who have been switched from&#xD;
             intravitreal ranibizumab to intravitreal VEGF Trap-EYE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any previous or concurrent history of treatment of other retinal&#xD;
             diseases with pharmacologic agents other than ranibizumab, including verteporfin&#xD;
             photodynamic therapy, bevacizumab, triamcinolone, or dexamethasone.&#xD;
&#xD;
          2. Patients with prior history of vitrectomy surgery in the study eye.&#xD;
&#xD;
          3. Patients enrolled in any previous or current clinical trial or study of any medication&#xD;
             for AMD or any other retinal vascular disease, including diabetic retinopathy or&#xD;
             retinal vein occlusion.&#xD;
&#xD;
          4. Ocular media opacity precluding proper retinal imaging&#xD;
&#xD;
          5. Inadequate pupillary dilation to achieve proper retinal imaging&#xD;
&#xD;
          6. Concurrent use of systemic anti-VEGF agents&#xD;
&#xD;
          7. CNV due to other causes, including histoplasmosis, uveitis, trauma, or myopia&#xD;
&#xD;
          8. Active or recent (&lt; 4 weeks) or recurrent inflammation in the eye&#xD;
&#xD;
          9. Current vitreous hemorrhage in the study eye limiting visualization of the fundus&#xD;
&#xD;
         10. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis&#xD;
&#xD;
         11. Untreated glaucoma with IOP &gt; 25 in the eye&#xD;
&#xD;
         12. Other ocular diseases that can compromise the visual acuity of the study eye such as&#xD;
             amblyopia and anterior ischemic optic neuropathy&#xD;
&#xD;
         13. Pregnancy or lactation&#xD;
&#xD;
         14. History of other disease, exam finding, or clinical laboratory that contraindicates&#xD;
             the use the drug&#xD;
&#xD;
         15. Current treatment for active systemic infection&#xD;
&#xD;
         16. Evidence of significant uncontrolled concomitant diseases such as cardiovascular&#xD;
             disease, pulmonary, renal, hepatic, endocrine, or GI disorders&#xD;
&#xD;
         17. History of recurrent significant infections or bacterial infections&#xD;
&#xD;
         18. Inability to comply with study or follow-up procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Theodore Leng</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

